/ /

  • linkedin
  • Increase Font
  • Sharebar

    Early results of trifocal IOL exhibit solid performance



    The most common adverse event was dry eye, which occurred in 13 patients in the first eye (8.7%), and 11 patients in the second eye (7.4%). One patient (0.7%) reported 2 serious adverse events of blurred vision and IOL extraction that were related to the study device.Visual acuity in logMAR and Snellen equivalent. Data reflect mean and 90% confidence intervals.

    The most common, non-serious adverse events related to the PanOptix IOL were halos (first eye, n=4 [2.7%], second eye, n=3 [2.0%]), and glare (first eye, n=2 [1.3%], second eye, n=2 [1.4%]). Seven patients (5%) had non-fatal serious adverse events, and 3 deaths were reported. The causes of death were myocardial infarction, acute myocardial infarction, and multi-organ failure–all unrelated to the study device or the study procedures.

    The researchers concluded the early results from this study show good visual performance (visual acuity better or equal to 20/25) of the AcrySof IQ PanOptix IOL across the whole range of defocus. At the 6-month visit, the binocular defocus curve for the IOL demonstrated approximate visual acuity of 20/25 or better from near (40 cm) through intermediate (60 cm) to distance. No unexpected adverse events were reported.


    Thomas Kohnen, MD, PhD

    E: [email protected]

    This article was adapted from a presentation that Dr. Kohnen delivered at the 2017 American Society of Cataract and Refractive Surgery meeting. Dr. Kohnen is a consultant and/or receives grants from Alcon Laboratories, Carl Zeiss Meditec, Geuder, Hoya, Johnson & Johnson Vision, Oculentis, Oculus, Optikgeräte, Santen GmbH, Schwind, STAAR Surgical, TearLab Corp., Thea Pharma, Thieme Compliance, and Ziemer Ophthalmology.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results